ARCT - Arcturus Therapeutics Holdings Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

ARCT

ARCTURUS THERAPEUTICS HOLDINGS INC.

NASDAQ

$13.79

▲ UP 7.11% (0.92)

KEY STATISTICS

Market Cap$366.09 M

52w High$24.17

52w Low$5.50

Dividend Yield1.29%

FrequencySpecial

P/E-4.16

Volume358.97K

Shares Out.28.42M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Joseph E. Payne

COMPENSATION 2026

Salary$750,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$0

Total$1,691,000

ABOUT

SECTOR

Healthcare

WENT PUBLIC

May 22, 2013

METHOD OF GOING PUBLIC

Reverse Merger

FULL TIME EMPLOYEES

109

PRICE TARGET

Target High$41.00

Target Low$20.00

Target Median$30.50

Target Consensus$30.50

UPCOMING EARNINGS

DateNov 9, 2026

DayMonday

Rev. Est.$8.00M

NOV

MON

SPLIT RECORD

DATE	TYPE	RATIO
2017-11-16	Reverse	1:7

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

72.56%

HOLDERS

212

TOP 8 OF 212 · RANKED BY POSITION SIZE

Federated Hermes, Inc.

4.7M sh

$86.51M

Ark Investment Management LLC

Sumitomo Mitsui Trust Holdings, Inc.

2.3M sh

$17.67M

Nikko Asset Management Americas, Inc.

Two Sigma Investments, LP

1.1M sh

$7.33M

PRICE

$13.79 ▲ UP 7.11% (+$0.92)

OVERLAYS

About Arcturus Therapeutics Holdings Inc.

https://arcturusrx.com ↗

Arcturus Therapeutics is an RNA medicines company developing vaccines and therapies for infectious, liver, and respiratory rare diseases, with multiple programs and collaborations worldwide.

INDUSTRY

Biotechnology

A PRODUCT ARCTURUS THERAPEUTICS HOLDINGS INC. IS KNOWN FOR

KOSTAIVE®

KOSTAIVE® is the first approved self-amplifying mRNA COVID-19 vaccine, licensed in Japan and the EU, showcasing Arcturus's sa-mRNA platform with potential for broader, durable infectious disease protection.

COMPETITORS

COMPETITOR

Arcturus Therapeutics Holdings in 2025

SENTIMENT: − NEGATIVE

REGULATORY · NOVEMBER 2025

Arcturus Therapeutics Indefinitely Delays U.S. FDA Filing for its COVID-19 Vaccine, KOSTAIVE®, Forcing Strategic Shift

Arcturus Therapeutics announced in its Q3 2025 financial update the indefinite delay of the U.S. Biologics License Application (BLA) for its COVID-19 vaccine, KOSTAIVE®, due to sudden changes in FDA regulatory requirements. This significant regulatory setback for a key commercial product prompted the company to implement additional cost-reduction measures to extend its cash runway and pivot focus towards its cystic fibrosis and OTC deficiency programs.

PRODUCT DISCONTINUATION · Q1-Q2 2025 · IN PROGRESS

Arcturus Therapeutics Pivots from Vaccines to Prioritize Rare Disease mRNA Therapeutics

In 2025, Arcturus Therapeutics made a significant strategic decision to deprioritize its early-stage vaccine programs for chlamydia, gonorrhea, and Lyme disease. This move was part of a broader portfolio rationalization to intensify focus and reallocate resources to its core mRNA therapeutic candidates for rare diseases, specifically ARCT-032 for cystic fibrosis and ARCT-810 for ornithine transcarbamylase (OTC) deficiency.